Annexin Pharmaceuticals AB (ANNX.ST) Stock Analysis & Winston Score

Annexin Pharmaceuticals is a Swedish biotech company that is developing experimental medicines to treat diseases caused by damaged blood vessels. Its main focus is a drug candidate called ANXV, which is based on a protein called Annexin A5 that the body naturally produces. The company is targeting serious conditions like retinal vein occlusion, which can cause blindness, and has no approved products on the market yet. Annexin does not currently sell anything, so it earns no revenue and relies entirely on raising money from investors to fund its research. It is a small, early-stage company based in Stockholm, Sweden, with operations focused on clinical trials in Europe. The company's potential edge is its proprietary platform built around Annexin A5, but the main risk is significant: it must successfully complete clinical trials, navigate regulatory approval, and secure enough funding before its cash runs out — all of which are uncertain outcomes for any early-stage biotech.